cell therapy trial for light chain amyloidosis
The first European clinical trial for CAR T-cell therapy in patients with light chain amyloidosis has launched in the UK. Researchers hope this treatment, which targets abnormal plasma cells, will provide a more effective option for patients who do not respond to standard chemotherapy.
Why it matters
Represents a potential breakthrough in treating a rare, life-threatening disease where current standard-of-care options are limited.
Three patients in the UK have become the first in Europe to receive CAR T-cell therapy for light chain amyloidosis (AL).
Objective reporting on medical research and clinical trial progress.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in